Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model.

Yongkun Zhao,Chong Wang,Boning Qiu,Chufang Li,Hualei Wang,Hongli Jin,Weiwei Gai,Xuexing Zheng,Tiecheng Wang,Weiyang Sun,Feihu Yan,Yuwei Gao,Qian Wang,Jinghua Yan,Ling Chen,Stanley Perlman,Nanshan Zhong,Jincun Zhao,Songtao Yang,Xianzhu Xia

DOI: https://doi.org/10.1016/j.antiviral.2016.11.016

IF: 7.6

2016-01-01

Antiviral Research

Abstract:Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary infection caused by a coronavirus (CoV), MERS-CoV. With the continuing spread of MERS-CoV, prophylactic and therapeutic treatments are urgently needed. In this study, we prepared purified equine F(ab')2 from horses immunized with MERS-CoV virus-like particles (VLPs) expressing MERS-CoV S, M and E proteins. Both IgG and F(ab')2 efficiently neutralized MERS-CoV replication in tissue culture. Passive transfer of equine immune antibodies significantly reduced virus titers and accelerated virus clearance from the lungs of MERS-CoV infected mice. Our data show that horses immunized with MERS-CoV VLPs can serve as a primary source of protective F(ab')2 for potential use in the prophylactic or therapeutic treatment of exposed or infected patients.